Results from a subgroup of the ICONIC-LEAD study show 75% of adolescents with plaque psoriasis achieved completely clear skin ...

The FDA has accepted Yuflyma as an interchangeable biosimilar to adalimumab for the treatment of multiple chronic ...

Good morning, and welcome to Johnson & Johnson's First Quarter 2025 Earnings Conference Call. All participants will be in listen-only mode until the question-and-answer session of the conference. This ...

New results from a subgroup analysis of the ICONIC-LEAD study showed icotrokinra was effective and safe for the treatment of moderate to severe plaque psoriasis in adolescents, according to a press ...

Icotrokinra is efficacious and safe for treating moderate to severe plaque psoriasis among adolescents and adults when compared with placebo.

Biocon Biologics Ltd (BBL), the biosimilars company and subsidiary of Biocon Ltd, has announced a licence agreement with Regeneron to commercialise Yesafili, a drug used to treat ophthalmological ...

Psoriasis shows on the skin, but it's a disease which goes a lot deeper and is linked to serious health problems. In recent years, newer targeted drugs are making a difference.

Managing psoriasis is more than going to your doctor's appointments. Learn from experts on how to improve your self-care.

Deucravacitinib has been observed as a safe and efficacious treatment for adults with moderate to severe plaque psoriasis for up to 4 years.

Organon Canada, a global healthcare company with a mission to improve the health of women throughout their lives, today announced that Health Canada has approved NDUVRA (tapinarof cream), 1%, the ...

Organon Canada, a global healthcare company with a mission to improve the health of women throughout their lives, today announced that Health Canada has approved NDUVRA (tapinarof cream), 1%, the ...